Title: Successful Use of Add-on Minocycline for Treatment of Persistent Negative Symptoms in Schizophrenia
Abstract: Back to table of contents Previous article Next article LettersFull AccessSuccessful Use of Add-on Minocycline for Treatment of Persistent Negative Symptoms in SchizophreniaKapil Jhamnani, M.D., Venkataram Shivakumar, M.D., Sunil Kalmady, M.D., Naren P Rao, M.D., and Ganesan Venkatasubramanian, M.D.Kapil Jhamnani, M.D., Venkataram Shivakumar, M.D., Sunil Kalmady, M.D., Naren P Rao, M.D., and Ganesan Venkatasubramanian, M.D.Published Online:1 Jan 2013https://doi.org/10.1176/appi.neuropsych.11120376AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Schizophrenia is a chronic neuropsychiatric disorder characterized by diversity of symptoms grouped into positive, negative, and cognitive spheres.1 Like the symptoms, the etiology of schizophrenia is also diverse. Among the various etiological hypotheses, immune system aberrations have been consistently implicated.2 C-reactive protein (CRP), a marker of inflammation, has been found to be high in schizophrenia patients, and its levels linked with the severity of negative symptoms and cognitive deficits in schizophrenia.3,4 Interestingly, minocycline, an antibiotic with immunomodulatory properties,5 has been reported to be useful as an adjunctive agent in acute and early phases of schizophrenia.6,7 To the best of our knowledge for the first time, herein, we describe two case reports in which minocycline was found to be useful as an add-on agent in treating persistent negative symptoms in schizophrenia with concurrent reduction in levels of CRP.Case Reports#1. "Mr. V," a 25-year-old man with a diagnosis of undifferentiated schizophrenia (ICD-10), presented with complaints of occupational dysfunction, along with features suggestive of persistent negative symptoms, namely, amotivation, alogia, anhedonia, apathy, affective blunting, and attention deficits, despite being treated with a combination of clozapine (300 mg/day) and amisulpride (100 mg/day) over the past 6 months. His psychopathology scores as assessed by Scale for Assessment of Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS) were 13 and 89, respectively. Hematological assessments, fasting blood sugar, lipid profile, liver, and renal function tests were normal. Serum C-reactive protein (CRP) level was found to be elevated (2.51 ng/mL). Minocycline (100 mg/day) was added to his ongoing treatment. After 3 months, the patient showed significant improvement in negative symptoms (SANS score: 62); he was also occupationally functional, with his functional status described by the mother as the best achieved by him over the past 8 years of illness. His repeat CRP level was found to be reduced (1.76 ng/mL). The patient maintained this improvement over a further follow-up period of 6 months.#2. "Ms. B," a 23-year-old woman with a diagnosis of paranoid schizophrenia (ICD-10), presented with complaints of attention and concentration deficits, discontinuation of her singing, and asociality for 1 year, with positive symptoms in remission while on risperidone (4 mg/day). Because of distressing weight gain, hirsutism, and hyperprolactinemia, risperidone was substituted with aripiprazole without worsening of positive symptoms. Her psychopathology assessment by Scale for Assessment of Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS) revealed scores of 10 and 26, respectively. Hematological assessments, fasting blood sugar, lipid profile, liver, and renal function tests were normal. Serum C-reactive protein (CRP) level was found to be elevated (3.7 ng/mL). Minocycline (100 mg/day) was added to her ongoing treatment. After 2 months, she showed significant improvement in negative symptoms (SANS score: 21); she also started singing and music, with improved attention, concentration, and social interaction, as reported by her parents. Her repeat CRP level was found to be reduced (2.7 ng/mL). The patient maintained this improvement over a further follow-up period of 2 months.DiscussionThese two case reports suggest the effective role of add-on minocycline in treating negative symptoms in schizophrenia patients with elevated serum CRP levels. Minocycline, besides being an antibiotic, also has the property of agonistic action on NMDA receptors.7 NMDA receptor hypofunctioning, leading to reduced glutaminergic transmission, has been shown to have a possible role in the negative symptoms and cognitive deficits in patients with schizophrenia.8 Interestingly, minocycline also possesses anti-inflammatory action,5 which possibly explains the decrease in CRP levels, and hence, symptom improvement. Thus, we conclude that minocycline can be used as an add-on therapy in schizophrenia with resistant negative symptoms and in patients with raised serum CRP levels.The Metabolic Clinic in Psychiatry, Department of Psychiatry Cognitive Neurobiology & Translational Psychiatry Laboratory, Neurobiology Research Centre National Institute of Mental Health & Neurosciences Bangalore, IndiaCorrespondence: G. Venkatasubramanian M.D.; e-mail: venkat.[email protected]comReferences1 Andreasen NC: Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995; 346:477–481Crossref, Medline, Google Scholar2 Müller N, Riedel M, Ackenheil M, et al.: The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 4):62–68Crossref, Medline, Google Scholar3 Dickerson F, Stallings C, Origoni A, et al.: C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007; 93:261–265Crossref, Medline, Google Scholar4 Fawzi MH, Fawzi MM, Fawzi MM, et al.: C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 2011; 190:91–97Crossref, Medline, Google Scholar5 Macdonald H, Kelly RG, Allen ES, et al.: Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973; 14:852–861Crossref, Medline, Google Scholar6 Levkovitz Y, Mendlovich S, Riwkes S, et al.: A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71:138–149Crossref, Medline, Google Scholar7 Miyaoka T, Yasukawa R, Yasuda H, et al.: Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:304–307Crossref, Medline, Google Scholar8 Shim SS, Hammonds MD, Kee BS: Potentiation of the NMDA receptor in the treatment of schizophrenia: focus on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008; 258:16–27Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited ByThe Gut MicrobiomeThe role of the gut microbiome in the development of schizophreniaSchizophrenia Research, Vol. 234Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry15 February 2021 | Behavioural Pharmacology, Vol. 32, No. 2&3Efficacy and Mechanism Evaluation, Vol. 6, No. 7Minocycline as an Evidence-Based Adjunct Treatment in SchizophreniaPsychiatric Annals, Vol. 48, No. 5Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels3 May 2017 | Psychiatric Quarterly, Vol. 89, No. 1Early Intervention in Psychiatry, Vol. 12, No. 4Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophreniaNeuropharmacology, Vol. 116Journal of Neural Transmission, Vol. 124, No. S1CNS Spectrums, Vol. 22, No. 5Translational Psychiatry, Vol. 7, No. 5Frontiers in Neuroscience, Vol. 11The Gut MicrobiomeAdjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent SymptomsJournal of Clinical Psychopharmacology, Vol. 35, No. 4, Vol. 3The Lancet Psychiatry, Vol. 2, No. 3Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 56Pharmacologia, Vol. 6, No. 8Brain, Behavior, and Immunity, Vol. 38Neuroscience, Vol. 266PLoS ONE, Vol. 9, No. 4PLoS ONE, Vol. 9, No. 6Clinical Psychopharmacology and Neuroscience, Vol. 12, No. 1Recent advances in psychoneuroimmunology relevant to schizophrenia therapeuticsCurrent Opinion in Psychiatry, Vol. 26, No. 5Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 44 Volume 25Issue 1 Winter 2013Pages E06-E07 Metrics PDF download History Published online 1 January 2013 Published in print 1 January 2013
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 38
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot